期刊
VIRUSES-BASEL
卷 13, 期 8, 页码 -出版社
MDPI
DOI: 10.3390/v13081532
关键词
viral cell entry; hepatitis B virus (HBV); hepatitis D virus (HDV); sodium taurocholate co-transporting polypeptide (NTCP); hepatoma cell lines; primary hepatocytes
类别
资金
- Agence Nationale de Recherches sur le Sida et les Hepatites Virales (ANRS) [ECTZ104527]
- French National Research Agency, Investments for the Future (Investissements d'Avenir) program [ANR-10-LAB-28]
Chronic hepatitis D is a severe form of chronic viral hepatitis with a high risk of hepatocellular carcinoma, resulting from co-infection of the liver with HBV and HDV. Current therapies only control HBV infection, while novel strategies are needed for efficient elimination of HDV.
Chronic hepatitis D is one of the most severe and aggressive forms of chronic viral hepatitis with a high risk of developing hepatocellular carcinoma (HCC). It results from the co-infection of the liver with the hepatitis B virus (HBV) and its satellite, the hepatitis D virus (HDV). Although current therapies can control HBV infection, no treatment that efficiently eliminates HDV is available and novel therapeutic strategies are needed. Although the HDV cycle is well described, the lack of simple experimental models has restricted the study of host-virus interactions, even if they represent relevant therapeutic targets. In the last few years, the discovery of the sodium taurocholate co-transporting polypeptide (NTCP) as a key cellular entry factor for HBV and HDV has allowed the development of new cell culture models susceptible to HBV and HDV infection. In this review, we summarize the main in vitro model systems used for the study of HDV entry and infection, discuss their benefits and limitations and highlight perspectives for future developments.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据